|MDACC Study No:||2011-0252 (clinicaltrials.gov NCT No: NCT01440998)|
|Title:||Pilot and Translational Study of Dasatinib (IND #73969, NSC#732517), Paclitaxel and Carboplatin in Women with Advanced Stage and Recurrent Endometrial Cancer|
|Principal Investigator:||Robert Coleman|
|Treatment Agent:||Carboplatin; Dasatinib; Paclitaxel|
|Study Description:||The goal of this clinical research study is to learn if dasatinib affects a |
gene called EphA2 in the tumor.
Researchers also want to learn how often and how severe the side effects of
dasatinib may be when given with paclitaxel and carboplatin, and if and how
long this combination may help to control endometrial cancer.